These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 31680767)

  • 1. Efficacy of evogliptin and cenicriviroc against nonalcoholic steatohepatitis in mice: a comparative study.
    Wang Z; Park H; Bae EJ
    Korean J Physiol Pharmacol; 2019 Nov; 23(6):459-466. PubMed ID: 31680767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis.
    Krenkel O; Puengel T; Govaere O; Abdallah AT; Mossanen JC; Kohlhepp M; Liepelt A; Lefebvre E; Luedde T; Hellerbrand C; Weiskirchen R; Longerich T; Costa IG; Anstee QM; Trautwein C; Tacke F
    Hepatology; 2018 Apr; 67(4):1270-1283. PubMed ID: 28940700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet-induced mouse model of nonalcoholic steatohepatitis.
    Kruger AJ; Fuchs BC; Masia R; Holmes JA; Salloum S; Sojoodi M; Ferreira DS; Rutledge SM; Caravan P; Alatrakchi N; Vig P; Lefebvre E; Chung RT
    Hepatol Commun; 2018 May; 2(5):529-545. PubMed ID: 29761169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention and treatment effect of evogliptin on hepatic steatosis in high-fat-fed animal models.
    Kim MK; Chae YN; Ahn GJ; Shin CY; Choi SH; Yang EK; Sohn YS; Son MH
    Arch Pharm Res; 2017 Feb; 40(2):268-281. PubMed ID: 27885461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gliptins Suppress Inflammatory Macrophage Activation to Mitigate Inflammation, Fibrosis, Oxidative Stress, and Vascular Dysfunction in Models of Nonalcoholic Steatohepatitis and Liver Fibrosis.
    Wang X; Hausding M; Weng SY; Kim YO; Steven S; Klein T; Daiber A; Schuppan D
    Antioxid Redox Signal; 2018 Jan; 28(2):87-109. PubMed ID: 28635324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective Effects of Evogliptin on Steatohepatitis in High-Fat-Fed Mice.
    Kim JH; Jang SJ; Roh GS; Cho HS; Kang H; Kim SK
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32937958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
    World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis.
    Witek RP; Stone WC; Karaca FG; Syn WK; Pereira TA; Agboola KM; Omenetti A; Jung Y; Teaberry V; Choi SS; Guy CD; Pollard J; Charlton P; Diehl AM
    Hepatology; 2009 Nov; 50(5):1421-30. PubMed ID: 19676126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis.
    Tacke F
    Expert Opin Investig Drugs; 2018 Mar; 27(3):301-311. PubMed ID: 29448843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocyte-specific sirtuin 6 deletion predisposes to nonalcoholic steatohepatitis by up-regulation of Bach1, an Nrf2 repressor.
    Ka SO; Bang IH; Bae EJ; Park BH
    FASEB J; 2017 Sep; 31(9):3999-4010. PubMed ID: 28536120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TRIF Differentially Regulates Hepatic Steatosis and Inflammation/Fibrosis in Mice.
    Yang L; Miura K; Zhang B; Matsushita H; Yang YM; Liang S; Song J; Roh YS; Seki E
    Cell Mol Gastroenterol Hepatol; 2017 May; 3(3):469-483. PubMed ID: 28462384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis.
    Duparc T; Briand F; Trenteseaux C; Merian J; Combes G; Najib S; Sulpice T; Martinez LO
    Am J Physiol Gastrointest Liver Physiol; 2019 Oct; 317(4):G508-G517. PubMed ID: 31460789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy.
    Kristiansen MN; Veidal SS; Rigbolt KT; Tølbøl KS; Roth JD; Jelsing J; Vrang N; Feigh M
    World J Hepatol; 2016 Jun; 8(16):673-84. PubMed ID: 27326314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial.
    Pedrosa M; Seyedkazemi S; Francque S; Sanyal A; Rinella M; Charlton M; Loomba R; Ratziu V; Kochuparampil J; Fischer L; Vaidyanathan S; Anstee QM
    Contemp Clin Trials; 2020 Jan; 88():105889. PubMed ID: 31731005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.
    Yamaguchi K; Yang L; McCall S; Huang J; Yu XX; Pandey SK; Bhanot S; Monia BP; Li YX; Diehl AM
    Hepatology; 2007 Jun; 45(6):1366-74. PubMed ID: 17476695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substitution of linoleic acid with α-linolenic acid or long chain n-3 polyunsaturated fatty acid prevents Western diet induced nonalcoholic steatohepatitis.
    Jeyapal S; Kona SR; Mullapudi SV; Putcha UK; Gurumurthy P; Ibrahim A
    Sci Rep; 2018 Jul; 8(1):10953. PubMed ID: 30026586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design.
    Friedman S; Sanyal A; Goodman Z; Lefebvre E; Gottwald M; Fischer L; Ratziu V
    Contemp Clin Trials; 2016 Mar; 47():356-65. PubMed ID: 26944023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sitagliptin attenuates methionine/choline-deficient diet-induced steatohepatitis.
    Jung YA; Choi YK; Jung GS; Seo HY; Kim HS; Jang BK; Kim JG; Lee IK; Kim MK; Park KG
    Diabetes Res Clin Pract; 2014 Jul; 105(1):47-57. PubMed ID: 24842243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intestinal TGR5 agonism improves hepatic steatosis and insulin sensitivity in Western diet-fed mice.
    Finn PD; Rodriguez D; Kohler J; Jiang Z; Wan S; Blanco E; King AJ; Chen T; Bell N; Dragoli D; Jacobs JW; Jain R; Leadbetter M; Siegel M; Carreras CW; Koo-McCoy S; Shaw K; Le C; Vanegas S; Hsu IH; Kozuka K; Okamoto K; Caldwell JS; Lewis JG
    Am J Physiol Gastrointest Liver Physiol; 2019 Mar; 316(3):G412-G424. PubMed ID: 30605011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the Therapeutic Potential of Cenicriviroc in the Treatment of Nonalcoholic Steatohepatitis with Fibrosis: A Brief Report on Emerging Data.
    Diaz Soto MP; Lim JK
    Hepat Med; 2020; 12():115-123. PubMed ID: 32884369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.